Diagine

# Diagine ## Overview - **Classification**: Broad-spectrum Topoisomerase Inhibitor Antibiotic - **Mechanism**: Inhibits bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication, repair, and transcription, leading to bacterial cell death. ## Primary Indications 1. **Community-Acquired Pneumonia (CAP)** - Treatment of adult and pediatric patients with mild-moderate CAP. 2. **Complicated Urinary Tract Infections (cUTI)** - Management of complicated UTIs, including pyelonephritis. 3. **Skin and Soft Tissue Infections (SSTI)** - Treatment of acute bacterial skin and soft tissue infections. ## Adult Dosing ### Standard Dosing **Community-Acquired Pneumonia (CAP) / Skin and Soft Tissue Infections (SSTI)** - **Dose**: **500 mg** - **Frequency**: Once daily (q24h) - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 7 to 10 days **Complicated Urinary Tract Infections (cUTI)** - **Dose**: **250 mg** - **Frequency**: Once daily (q24h) - **Route**: Oral (PO) or Intravenous (IV) - **Duration**: 3 to 5 days ### Dose Adjustments - **Renal Impairment**: - CrCl **30-50 mL/min**: Reduce dose by 25%. - CrCl **<30 mL/min** (including ESRD/dialysis): Reduce dose by 50%. - Administer after hemodialysis on dialysis days. - **Hepatic Impairment**: - Mild to moderate: No dose adjustment needed. - Severe: Use with caution, monitor liver function tests (LFTs) closely. - **Elderly Patients**: No specific dose adjustment based on age alone, but consider age-related renal function decline. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: Not generally recommended. - **Frequency**: N/A - **Maximum**: N/A - **Special Notes**: Use only if benefits outweigh risks in life-threatening infections where no safer alternatives exist, due to potential musculoskeletal adverse effects. ### Infants (1-12 months) - **Dose**: **7.5 mg/kg** - **Frequency**: Once daily (q24h) - **Maximum**: **250 mg/day** - **Special Notes**: Monitor closely for arthropathy. Oral suspension available. ### Children (1-12 years) - **Dose**: **10 mg/kg** - **Frequency**: Once daily (q24h) - **Maximum**: **500 mg/day** - **Special Notes**: Counsel on monitoring for joint pain or swelling. ### Adolescents (13-18 years) - **Dose**: Align with **adult dosing**, typically **500 mg** for most indications. - **Frequency**: Once daily (q24h) - **Maximum**: **500 mg/day** - **Special Notes**: Monitor for musculoskeletal adverse effects similar to adults. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Diagine or other topoisomerase inhibitor antibiotics. - **Absolute**: History of tendon disorders (e.g., tendonitis, rupture) associated with quinolones. - **Absolute**: Concurrent use with Class IA or Class III antiarrhythmics or other QTc-prolonging drugs. - **Relative**: History of myasthenia gravis (may exacerbate muscle weakness). ### Common Adverse Effects - **Very Common (>10%)**: Nausea, Diarrhea, Headache. - **Common (1-10%)**: Dizziness, Insomnia, Vomiting, Abdominal pain, Rash. - **Serious but Rare**: Tendon rupture (Achilles, shoulder, hand), QTc prolongation leading to Torsades de Pointes, Peripheral neuropathy, _Clostridioides difficile_ infection (CDI), Seizures, Hypoglycemia/Hyperglycemia, Photosensitivity. ### Key Drug Interactions - **Antacids, Sucralfate, Metal Cations (Fe, Zn, Mg, Al, Ca)**: - **Effect**: Reduced oral absorption of Diagine. - **Monitoring**: Separate administration by at least **2 hours before** or **4 hours after** Diagine. - **Warfarin**: - **Effect**: Enhanced anticoagulant effect, increased risk of bleeding. - **Monitoring**: Frequent INR monitoring, adjust warfarin dose as needed. - **QTc-prolonging Drugs (e.g., Amiodarone, Sotalol, Cisapride)**: - **Effect**: Additive QTc prolongation, increased risk of arrhythmias. - **Clinical Significance**: Avoid co-administration if possible. If unavoidable, monitor ECG and electrolytes closely. - **Corticosteroids**: - **Effect**: Increased risk of tendon rupture. - **Clinical Significance**: Co-administration generally discouraged, especially in elderly or transplant patients. ## Monitoring & Follow-up - **Before Treatment**: - Renal function (BUN, Cr, CrCl). - Liver function tests (ALT, AST, ALP, Bilirubin). - Electrolytes (K, Mg) if QTc risk factors present. - ECG if risk factors for QTc prolongation or cardiac disease. - **During Treatment**: - Monitor for signs/symptoms of adverse effects (e.g., tendon pain, neuropathy, psychiatric changes). - Renal function if prolonged treatment or co-administered nephrotoxins. - Clinical response to therapy (resolution of infection). - Repeat culture/sensitivity if no clinical improvement. - **Clinical Signs**: Watch for new-onset joint pain, numbness/tingling, severe diarrhea, palpitations, or mood changes. ## Clinical Pearls - 💡 **Tendon Rupture Risk**: Counsel patients on the immediate discontinuation of Diagine and seeking medical attention at the first sign of tendon pain, swelling, or inflammation. - 💡 **Administration Timing**: Take Diagine with plenty of fluids. Avoid taking with dairy products, antacids, or mineral supplements to ensure proper absorption. - 💡 **Photosensitivity**: Advise patients to avoid excessive sun exposure and use sunscreen due to potential for photosensitivity reactions. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.